Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Receives Average Recommendation of “Moderate Buy” from Analysts

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) has been assigned an average rating of “Moderate Buy” from the nineteen analysts that are presently covering the company, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating, thirteen have assigned a buy rating and three have assigned a strong buy rating to the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $109.25.

A number of equities research analysts have commented on GPCR shares. Wolfe Research started coverage on Structure Therapeutics in a research report on Thursday, March 26th. They issued a “peer perform” rating on the stock. HC Wainwright reduced their target price on Structure Therapeutics from $114.00 to $100.00 and set a “buy” rating on the stock in a research report on Monday, March 16th. Wall Street Zen downgraded Structure Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Weiss Ratings restated a “sell (d-)” rating on shares of Structure Therapeutics in a research report on Tuesday, April 21st. Finally, BMO Capital Markets set a $145.00 target price on Structure Therapeutics and gave the company an “outperform” rating in a research report on Tuesday, March 17th.

Structure Therapeutics Stock Up 1.0%

NASDAQ:GPCR opened at $39.19 on Friday. Structure Therapeutics has a 52 week low of $15.80 and a 52 week high of $94.90. The company has a market capitalization of $2.78 billion, a P/E ratio of -45.05 and a beta of -1.31. The stock’s fifty day moving average is $46.77 and its two-hundred day moving average is $56.65.

Structure Therapeutics (NASDAQ:GPCR) last posted its earnings results on Thursday, May 7th. The company reported ($0.35) EPS for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.04. Sell-side analysts anticipate that Structure Therapeutics will post -1.29 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Structure Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Bank of America Corp DE raised its holdings in shares of Structure Therapeutics by 617.0% in the 1st quarter. Bank of America Corp DE now owns 227,132 shares of the company’s stock valued at $10,948,000 after buying an additional 195,454 shares during the period. Janus Henderson Group PLC raised its holdings in shares of Structure Therapeutics by 5.2% in the 1st quarter. Janus Henderson Group PLC now owns 5,354,981 shares of the company’s stock valued at $258,260,000 after buying an additional 264,833 shares during the period. Eversept Partners LP raised its holdings in shares of Structure Therapeutics by 8.2% in the 1st quarter. Eversept Partners LP now owns 138,036 shares of the company’s stock valued at $6,653,000 after buying an additional 10,475 shares during the period. The Manufacturers Life Insurance Company raised its holdings in shares of Structure Therapeutics by 19.1% in the 1st quarter. The Manufacturers Life Insurance Company now owns 114,814 shares of the company’s stock valued at $5,534,000 after buying an additional 18,427 shares during the period. Finally, Orbimed Advisors LLC raised its holdings in shares of Structure Therapeutics by 27.0% in the 1st quarter. Orbimed Advisors LLC now owns 1,475,403 shares of the company’s stock valued at $71,114,000 after buying an additional 313,600 shares during the period. Hedge funds and other institutional investors own 91.78% of the company’s stock.

Structure Therapeutics Company Profile

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.